“Two-for-one” cancer immunotherapy more effective and at least as safe as standard treatments

  • Post author:
  • Post category:uncategorized

A "two-for-one" cancer immunotherapy is potentially more effective and at least as safe as standard immunotherapies, physician-scientists from UPMC Hillman Cancer Center who led an international, early-phase clinical trial report…

Continue Reading“Two-for-one” cancer immunotherapy more effective and at least as safe as standard treatments

CAR T-cell therapy for multiple myeloma shows no difference in survival outcomes by race and ethnicity

  • Post author:
  • Post category:uncategorized

Patients with multiple myeloma treated with idecabtagene vicleucel, known as "ide-cel," a chimeric antigen receptor (CAR) T-cell therapy, had no difference in overall survival outcomes regardless of race and ethnicity,…

Continue ReadingCAR T-cell therapy for multiple myeloma shows no difference in survival outcomes by race and ethnicity